Neurodermatitis clinical trials
The registry lists 22 studies for Neurodermatitis across more than 10 countries. 3 are recruiting or about to start. 11 of them are mainly about Neurodermatitis (how this is decided). Per ClinicalTrials.gov, last updated 2026-09-22.
Get an email when these change. Save the Neurodermatitis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Sanofi (4) · Cairo University (2) · Galderma R&D (2) · Prime Gene Therapeutics Co., Ltd. (2) · GWT-TUD GmbH (1) · Kamari Pharma Ltd (1) · Vanderbilt University Medical Center (1) · Genentech, Inc. (1)
What is being tested here
Drugs under test in Neurodermatitis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The study
- Dec 2026A Phase I Clinical Trial to Evaluate the Single Dose Ascending and Food Effects of PG-033 in Healthy Adults · Prime Gene Therapeutics Co., Ltd.
Who these studies take
Of the 1 Neurodermatitis studies recruiting now, 0 (0%) set no upper age limit and 1 (100%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (100%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 1 (100%) | 1 (100%) |
| 30 | 1 (100%) | 1 (100%) |
| 40 | 1 (100%) | 1 (100%) |
| 50 | 0 (0%) | 0 (0%) |
| 65 | 0 (0%) | 0 (0%) |
| 75 | 0 (0%) | 0 (0%) |
| 85 | 0 (0%) | 0 (0%) |
Across all 22 studies, recruiting or not: 50% stop at 75 or younger and 27% at 65; 18% take children; 5% are for women only and 0% for men only; 27% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 22 of 22. search them.
- A Phase I Clinical Trial to Evaluate the Single Dose Ascending and Food Effects of PG-033 in Healthy AdultsRecruitingNCT07013097Phase 11 country
- A Study to Evaluate the Multiple Dose Ascending of PG-033 in Healthy Adult Participants.Not yet recruitingNCT07619183Phase 11 country
- Fractional Carbon Dioxide Laser: A Novel Therapeutic Option for Lichen Simplex ChronicusNot yet recruitingNCT06267066Not applicable1 country
- Efficacy and Safety of HA35 Gel for Ultra-Rapid Skin Pruritus ReliefCompletedNCT07580911Not applicable1 country
- A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)CompletedNCT06687980Phase 317 countries
- A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)CompletedNCT06687967Phase 317 countries
- Effect of Extracorporeal Shockwave Therapy on Pruritus in Neurodermatitis PatientsCompletedNCT07206680Not applicable1 country
- Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)CompletedNCT04183335Phase 38 countries
- Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)CompletedNCT04202679Phase 311 countries
- A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic DiseasesCompletedNCT03858634Phase 21 country
- Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)CompletedNCT04501666Phase 310 countries
- A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)CompletedNCT04501679Phase 39 countries
- The Novel Electrolyzed Water Spray Treatment Mild Senile Groin Eczema, Neurodermatitis and PsoriasisCompletedNCT05770271Not applicable1 country
- KM-001 Cream for Treatment of Pruritus in Adult Patients With Lichen Simplex Chronicus (LSC)CompletedNCT05454462Phase 11 country
- A First-In-Human Study to Evaluate the Safety, Tolerability, and Efficacy of Si-544 in Adults With Atopic DermatitisCompletedNCT05383378Phase 11 country
- Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic DermatitisCompletedNCT03568136Phase 21 country
- Pain Outcomes Following Intralesional Corticosteroid InjectionsCompletedNCT03630198Phase 41 country
- Diagnostic Accuracy of "Three Rings Vulvoscopy" for Detection of Vulvar DermatosisCompletedNCT02732145Not applicable1 country
- Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality DisorderCompletedNCT01912391Phase 31 country
- Dapsone Prurigo StudyStatus unknownNCT01870050Not applicable1 country
- Investigation of Efficacy and Safety of EPOGAMCompletedNCT00878670Phase 41 country
- Study About Effectiveness of Silver-Containing Textiles for Treatment of Acute NeurodermatitisCompletedNCT00196430Phase 31 country